Referenten

Prof. Dr. med. Peter Borchmann
Prof. Dr. med. Peter Borchmann


Uniklinik Köln

Non-Hodgkin-Lymphome: DLBCLarrow_right_alt

Disclosures

  • Consultancy: Novartis, TAKEDA, Celgene, MSD
  • Research Funding: Novartis, TAKEDA, MSD
  • Honoraria: TAKEDA, Novartis, Gilead, Janssen, Amgen, Roche, MSD, BMS, Miltenyi Biotech
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Lars Bullinger
Prof. Dr. med. Lars Bullinger


Charité – Universitätsklinik Berlin

Akute Myeloische Leukämiearrow_right_alt

Disclosures

  • Consultancy: not applicable
  • Research Funding: Bayer
  • Honoraria: Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Seattle Genetics
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Martin Dreyling
Prof. Dr. med. Martin Dreyling


Klinikum der Universität München

Non-Hodgkin-Lymphome: FL, MCL und anderearrow_right_alt

Disclosures

  • Consultancy: Celgene, Janssen, Mundipharma, Roche
  • Research Funding: not applicable
  • Honoraria: Bayer, Celgene, Gilead, Janssen, Roche
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: Acerta, Bayer, Celgene, Gilead, Janssen, Novartis, Roche, Sandoz
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Barbara Eichhorst
Prof. Dr. med. Barbara Eichhorst


Uniklinik Köln

Chronische Lymphatische Leukämiearrow_right_alt

Disclosures

  • Consultancy: Janssen, Gilead, Roche, Abbvie, Novartis, Celgene, Arqule, AstraZeneca
  • Research Funding: Roche, Janssen, Abbvie, Gilead, Beigene
  • Honoraria: Roche, Abbvie, Gilead, Janssen, Celgene, Pharmacyclics, Hexal
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Andreas Engert
Prof. Dr. med. Andreas Engert


Uniklinik Köln

Hodgkin Lymphomarrow_right_alt

Disclosures

  • Consultancy: Takeda/Millennium, BMS
  • Research Funding Takeda/Millennium, BMS, Affimed
  • Honoraria: Takeda/Millennium, BMS, MSD, ADC-Therapeutics
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: Vaximm
  • Discussion of off-label drug use: Yes
Dr. med. Nicola Gökbuget
Dr. med. Nicola Gökbuget


Universitätsklinikum Frankfurt am Main

Akute Lymphatische Leukämiearrow_right_alt

Disclosures

  • Consultancy: AMGEN, Incyte, Novartis, Jazz Pharmaceuticals, Erytech, Celgene, Kite/Gilead, Servier, Pfizere
  • Research Funding: AMGEN, Incyte, Jazz Pharmaceuticals, Novartis, Servier, Pfizer
  • Honoraria (Invited Speaker): AMGEN, Novartis, Pfizer, Jazz Pharmaceuticals, Servier
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Hartmut Goldschmidt
Prof. Dr. med. Hartmut Goldschmidt


Universitätsklinikum Heidelberg

Multiples Myelomarrow_right_alt

Disclosures

  • Consultancy: Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda
  • Research Funding: Amgen, BMS, Celgene, Chugai, Janssen, Molecular Partners, MSD, Sanofi, Mundipharma, Takeda, Novartis
  • Honoraria: BMS, Celgene, Chugai, Janssen, Novartis, Sanofi
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Martin Griesshammer
Prof. Dr. med. Martin Griesshammer


Johannes Wesling Universitätsklinikum, Minden

Myeloproliferative Neoplasienarrow_right_alt

Disclosures

  • Consultancy: not applicable
  • Research Funding: not applicable
  • Honoraria: Amgen, Janssen, Novartis, Roche, Shire, AOP orphan, Celgene, CTI
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Wolf-Karsten Hofmann
Prof. Dr. med. Wolf-Karsten Hofmann


Universitätsmedizin Mannheim

Myelodysplastisches Syndromarrow_right_alt

Disclosures

  • Consultancy: Apogenix
  • Research Funding: Celgene, Novartis, Apogenix
  • Honoraria: : Celgene, Novartis
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Nicolaus Kröger
Prof. Dr. med. Nicolaus Kröger


Universitätsklinikum Hamburg-Eppendorf

Stammzelltransplantation / Gvhdarrow_right_alt

Disclosures

  • Consultancy: Medac, Jazz
  • Research Funding: Neovii, Celgene , Riemser , Novartis, Sanofi
  • Honoraria: Neovii, Novartis, Riemser, Sanofi, Jazz
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Philipp Le Coutre
Prof. Dr. med. Philipp Le Coutre


Charité – Universitätsklinik Berlin

Hämoglobinopathien / Sichelzellerkrankung

Disclosures

  • Consultancy: not applicable
  • Research Funding: not applicable
  • Honoraria: Novartis, BMS, Pfizer, Incyte, AOP
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Axel Matzdorff
Prof. Dr. med. Axel Matzdorff


Asklepios Klinikum Uckermark

Immunthrombozytopeniearrow_right_alt

Disclosures

  • Consultancy: AMGEN, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Leo Pharma, Novartis
  • Research Funding: Leo Pharma
  • Honoraria: AMGEN, Aspen, Astra, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai, Gilead, GlaxoSmithKline, Janssen, Leo Pharma, MSD, Mundipharma, Novartis, Pfizer, Sanofi, Roche
  • Patents and Royalties: not applicable
  • Equity ownership: Family owns shares from Roche
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: Yes
Prof. Dr. med. Andreas Reiter
Prof. Dr. med. Andreas Reiter


Universitätsmedizin Mannheim

Fortgeschrittene Systemische Mastozytosearrow_right_alt

Disclosures

  • Consultancy: Novartis, Blueprint, Deciphera, Incyte, CTI
  • Research Funding: Novartis
  • Honoraria: Novartis, Blueprint, Deciphera, Incyte, CTI
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable
Prof. Dr. med. Susanne Saußele
Prof. Dr. med. Susanne Saußele


Universitätsmedizin Mannheim

Chronische Myeloische Leukämiearrow_right_alt

Disclosures

  • Consultancy: not applicable
  • Research Funding: BMS, Novartis, Incyte
  • Honoraria: BMS, Incyte, Novartis, Pfizer
  • Patents and Royalties: not applicable
  • Membership on an entity’s Board of Directors or advisory committees: not applicable
  • Discussion of off-label drug use: not applicable